BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

GKOS upcoming catalysts

Glaukos Corporation: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to GKOS (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-01-27FDA approvalapprovedGLAUKOS GKOSIDOSE TRApproved 2026-01-27: IDOSE TR (NDA218010 SUPPL4)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09 est.P2Glaukos Corporation GKOSNCT07400965 Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisDemodex Blepharitisrecruiting250
2025-12 est.P2Glaukos Corporation GKOSNCT05966493 A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDPersistent Corneal Epithelial Defectrecruiting84

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.